EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 5, 2008, Pages 1039-1047

  Giammarile, Francesco ^a   Chiti, Arturo ^b   Lassmann, Michael ^c   Brans, Boudewijn ^d   Flux, Glenn ^e  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Guidelines; MIBG; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIGLAUCOMA AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; DECONGESTIVE AGENT; INOTROPIC AGENT; IODINE; LABETALOL; LUGOL; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; POTASSIUM IODATE; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; RESERPINE; SEDATIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

ADRENERGIC SYSTEM; AGE DISTRIBUTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARCINOID; CAREGIVER; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG LABELING; DRUG UPTAKE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ECHOGRAPHY; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IONIZING RADIATION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKEMIA; LIFE EXPECTANCY; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROECTODERM TUMOR; NEUROENDOCRINE SYSTEM; NUCLEAR MEDICINE; NURSING STAFF; PARAGANGLIOMA; PATIENT INFORMATION; PERSONAL MONITORING; PHEOCHROMOCYTOMA; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREGNANCY; RADIATION PROTECTION; RADIATION SAFETY; REVIEW; SCINTIGRAPHY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME;

EID: 42149117808     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0715-3     Document Type: Review

References (24)

1. Wafelman AR, et al. Radio-iodinated MIBG: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.
2. Weiland DM, Wu J, Brown LE, Manger TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I meta-iodobenzylguanidine. J Nucl Med 1980;21:349-53.
3. Beierwaltes WH. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives. Med Pediatr Oncol 1987;15:188-91.
4. Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 1995;22(10):1180-3 (Oct).
5. Hoefnagel CA, Lewington VJ. MIBG therapy. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. vol 2. 2nd ed. New York: Churchill Livingstone; 1998. p. 1067-81.
6. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-MIBG. Cancer 2003;97(5):1332-8 (Mar 1).
7. Radiation Protection, European Commission. Radiation protection following iodine-131 therapy (Exposures due to outpatients or discharged inpatients). Radiation Protection 97.
8. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of I-131-MIBG therapy FOR in the treatment of children with stage 4 neuroblastoma? Nuklearmedizin 2006;45(4):145-51.
9. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
10. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25(9):1054-60 Mar 20.
11. Royal HD, Pierson JR, Fletcher JW, et al. Procedure guideline for guideline development. J Nucl Med 1996;37:878-81.
12. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller ST, Kemshead JT, et al. Phase I/II study of iodine-131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-96.
13. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumour and whole-body dosimetry with tumour response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42(11):1713-21. Nov.
14. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20(2):195-9.
15. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-MIBG therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 2003;25(7):543-7 (Jul).
16. Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA. Patient dosimetry after I-131-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun 2001;22(4):367-74.
17. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47(17):3211-23.
18. Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18(1):81-7.
19. Fielding SL, Flower MA, et al. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308-16.
20. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, et al. Dosimetry for fractionated I131-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 2007;22(1):105-12.
21. Chittenden S, Pratt B, Pomeroy K, Black P, Long C, Smith N, et al. Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm 2007;22(2):247-53.
22. MIRD Committee of Society of Nuclear Medicine. MIRD Dose Estimate Report No. 5. J Nucl Med 1975;16:587.
23. International Committee on Radiological Protection, ICRP Publication 53, Radiation dose to patients from radiopharmaceuticals, Annals of the ICRP, 18, 1-4 (1987).
24. International Committee on Radiological Protection, ICRP Publication 60, Recommendations of the International Commission on Radiological Protection, Annals of the ICRP, 21, 1-3 (1991).